https://www.selleckchem.com/pr....oducts/tauroursodeox
050; 95% confidence interval 0.002, 0.099; p = 0.04) and length-for-age z-score (mean difference 0.062; 95% confidence interval 0.013, 0.111; p = 0.01) during the first 6 months of life but not thereafter. Prenatal or postnatal MMS did not have benefits for other child outcomes. Whereas maternal MMS is a proven strategy to prevent adverse birth outcomes, other approaches may also need to be considered to curb the high burdens of child morbidity and growth faltering. Whereas maternal MMS is a proven strategy to prevent
Like
Comment
Share
